| Literature DB >> 31337664 |
Ling-Shiang Chuang1,2, Joshua Morrison1,3, Nai-Yun Hsu1,2, Philippe Ronel Labrias1, Shikha Nayar1, Ernie Chen1,2, Nicole Villaverde1, Jody Ann Facey1, Gilles Boschetti4, Mamta Giri1, Mireia Castillo-Martin5, Tin Htwe Thin5, Yashoda Sharma1, Jaime Chu3, Judy H Cho6,2.
Abstract
Genome-wide association studies have identified over 200 genomic loci associated with inflammatory bowel disease (IBD). High-effect risk alleles define key roles for genes involved in bacterial response and innate defense. More high-throughput in vivo systems are required to rapidly evaluate therapeutic agents. We visualize, in zebrafish, the effects on epithelial barrier function and intestinal autophagy of one-course and repetitive injury. Repetitive injury induces increased mortality, impaired recovery of intestinal barrier function, failure to contain bacteria within the intestine and impaired autophagy. Prostaglandin E2 (PGE2) administration protected against injury by enhancing epithelial barrier function and limiting systemic infection. Effects of IBD therapeutic agents were defined: mesalamine showed protective features during injury, whereas 6-mercaptopurine displayed marked induction of autophagy during recovery. Given the highly conserved nature of innate defense in zebrafish, it represents an ideal model system with which to test established and new IBD therapies targeted to the epithelial barrier.This article has an associated First Person interview with the first author of the paper.Entities:
Keywords: Crohn's disease; DSS injury model; Epithelial barrier; IBD; Lysosome-rich enterocytes
Year: 2019 PMID: 31337664 PMCID: PMC6737949 DOI: 10.1242/dmm.037432
Source DB: PubMed Journal: Dis Model Mech ISSN: 1754-8403 Impact factor: 5.758
Fig. 1.Impaired recovery of acidic-lysosome function and mucin production after repeated DSS injury in zebrafish intestines. (A) Dose-dependent mortality observed after repeated DSS injury (N=1739 from 11 clutches). Compared to the single DSS injury, which has a 98-100% survival rate (day 6), repeated DSS injury induces a high mortality rate of 63% in 0.25% DSS and 29% in 0.1% DSS. (B) Hematoxylin and eosin (H&E) staining of a longitudinal section of zebrafish larvae intestine. A total of 20 larvae per experimental condition were embedded in paraffin and sectioned at 10 μm per slide. Scale bars: 100 μm. (C,D) Quantification of Neutral Red images (top panels) and Neutral Red accumulation (bottom panel) for single (C) and repeated (D) DSS-injured zebrafish. Neutral Red accumulation in the intestine indicates normally functioning acidic lysosomes. The damage to lysosomal function is fully recovered within 2 days with the single DSS injury (C; N=253 from four clutches) but is impaired with the repeated DSS injury (D; N=137 from three clutches; day 2 N=5 out of 13 from single clutch due to high mortality rate of 61.5%). Neutral Red images for single (C) and repeated (D) injury are shown as control, and 0.1% and 0.25% (w/v) DSS treatments at treatment times of 1 day and 2 days after injury. Scale bars: 100 µm. ***P<0.001, **P<0.01, *P<0.05. Error bars, mean±s.e.m. (E) Images (left panel) and quantification (right panel) of Alcian Blue staining of intestine with single and repeated injury with control and 24 h after removal from DSS treatment. The quantification of total Alcian Blue intensity from single (N=160 from three clutches) and repeated (N=154 from three clutches) injury is shown. There was an increase in mucin production after single DSS injury, but mucin production was impaired after repeated DSS injury. Scale bars: 100 µm.
Fig. 2.Lysosome-rich enterocyte-mediated bacterial protein uptake and autophagy with injury and bacterial exposure. (A) Bright-field, fluorescent and merged images of pHrodo-labeled heat-killed E. coli K12 MG1655 within a zebrafish larval intestine with and without DSS treatment. A total of 20 larva from each experimental condition were treated with the pHrodo-labeled E. coli proteins. The pHrodo dye is a pH-sensing dye indicating ingested E. coli proteins. Scale bars: 50 μm. The quantification is shown at the 0 h time point of Fig. 3G. (B) Uptake of E. coli proteins (red) colocalized with Cyto-ID-positive autophagosomes (green) in intestine. Scale bars: 20 μm. (C) Quantification of Cyto-ID intensities immediately following single (top panel) and repeated DSS injury (bottom panel). DSS [0.05% and 0.1% (w/v)] was applied at the beginning of treatment. ***P<0.001. Error bar, mean±s.e.m. (D) Cyto-ID intensities measured 1 day after DSS treatment shows recovery and non-recovery after single (top panel) and repeated (bottom panel) DSS injury. Altogether for C and D, N=544 from six clutches. ***P<0.001. **P<0.01. Error bar, mean±s.e.m. (E) High levels of mortality with E. coli treatment following single DSS injury. The left panel plots mortality rates at 1, 2 and 3 h after exposure to heat-killed E. coli labeled with Alexa Fluor 488 (green fluorescence) following single DSS injury. *P<0.05, comparing mortality rates at each time point with and without DSS treatment. N=341 from three clutches. Error bar, mean±s.e.m. The right panel shows systemic penetration of E. coli in the dorsal aorta (upper arrow) and posterior cardinal vein (lower arrow) with DSS treatment imaged 90 min after heat-killed E. coli treatment. Scale bars: 20 µm. Full bacterial invasion videos are shown in Movies 6 and 7.
Fig. 3.Effects of PGE2 and commonly utilized IBD medications on barrier function, bacterial containment and LRE function. (A-C) PGE2 induces mucin expression and release in a dose-dependent manner. (A) The images of Alcian Blue staining with treatments of 0.1, 1 and 10 μM PGE2. The quantification of the whole gut region is shown in B, and the red boxes indicate the quantification areas in C. Scale bars: 100 μm. Alcian Blue intensities of the full intestine (B) and the intestinal lumen (C) are shown (N=100 from three clutches). **P<0.01. ***P<0.001. Error bar, mean±s.e.m. (D) Quantification of relative Alcian Blue intensity in a human enteroid differentiated epithelial monolayer with and without 1 μM PGE2 treatment. ***P<0.001. N=3 patients with three biopsies each. (E-G) Experiment design of DSS and PGE2 treatment (E) for mortality assays (F) or ingested pHrodo-labeled E. coli protein intensity (G). *P<0.05. **P<0.01. N=1145 from nine clutches. Error bar, mean±s.e.m. (G) Fluorescent intensity of ingested pHrodo-labeled E. coli proteins 1, 2 and 3 h after removal from DSS. N=240 from three clutches. Error bar, mean±s.e.m. (H) Applying PGE2 (left panels), mesalamine (middle panels) and 6-mercaptopurine (right panels) to the DSS injury model. The relative Neutral Red (top panels) and Cyto-ID (bottom panels) intensities with treatment alone (dark blue), with treatment during DSS injury for 24 h (light green) and with 5 h of treatment after DSS removal (light blue) are reported relative to untreated controls. **P<0.01. ***P<0.001. Neutral-Red–PGE2, N=505 from three clutches. Neutral-Red–mesalamine, N=695 from six clutches. Neutral-Red–6-mercaptopurine, N=705 from three clutches. Cyto-ID–PGE2, N=196 from three clutches. Cyto-ID–mesalamine, N=189 from three clutches. Cyto-ID–6-mercaptopurine, N=213 from three clutches. Error bar, mean±s.e.m.
Fig. 4.Effects of PGE2 on mucus production and barrier protection. In healthy intestine, the mucus layer prevents microbes/microbial products from making contact with the epithelial barrier. With DSS injury, the mucus is depleted and the epithelial barrier is damaged, allowing microbes/microbial products access to the barrier. Escherichia coli incubation following DSS treatment yields increased E. coli in the intestine and increased bacterial contact with the epithelial cells. PGE2 rescues loss of the mucus layer due to DSS injury, preventing E. coli from reaching the epithelial barrier.